CompletedPhase 2

A Pilot Trial to Determine the Efficacy of VSL#3 for Reducing Colonization by VRE

United States90 participantsStarted 2008-10

Plain-language summary

The purpose of this study is to investigate the feasibility, safety and efficacy of oral probiotic, VSL#3 versus oral placebo for reducing colonization by VRE.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * subjects will be male or female * 18 years of age or older * may or may not be hospitalized * able to take oral medications * have been found to be colonized with VRE or at high risk of being colonized by VRE and are not taking antibiotics Exclusion Criteria: * people on antibiotics will not be eligible to participate

What they're measuring

The main outcomes will be the proportion of patients colonized with VRE at 4 weeks, 8 weeks, 12 weeks and 24 weeks following start of treatment.

Timeframe: 24 weeks

Trial details

NCT IDNCT00933556

SponsorUniversity of Wisconsin, Madison

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2010-10

View on ClinicalTrials.gov More Anti-biotic Resistance trials